JP2022506113A5 - - Google Patents
Info
- Publication number
- JP2022506113A5 JP2022506113A5 JP2021523282A JP2021523282A JP2022506113A5 JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5 JP 2021523282 A JP2021523282 A JP 2021523282A JP 2021523282 A JP2021523282 A JP 2021523282A JP 2022506113 A5 JP2022506113 A5 JP 2022506113A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- oxybutynin
- hydroxyatomoxetine
- receptor antagonist
- muscarinic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062027A JP2024088740A (ja) | 2018-10-31 | 2024-04-08 | 睡眠時無呼吸を治療するための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753420P | 2018-10-31 | 2018-10-31 | |
| US62/753,420 | 2018-10-31 | ||
| PCT/US2019/043065 WO2020091862A1 (en) | 2018-10-31 | 2019-07-23 | Methods and compositions for treating sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062027A Division JP2024088740A (ja) | 2018-10-31 | 2024-04-08 | 睡眠時無呼吸を治療するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506113A JP2022506113A (ja) | 2022-01-17 |
| JP2022506113A5 true JP2022506113A5 (cg-RX-API-DMAC7.html) | 2022-07-27 |
Family
ID=67539629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523282A Pending JP2022506113A (ja) | 2018-10-31 | 2019-07-23 | 睡眠時無呼吸を治療するための方法及び組成物 |
| JP2024062027A Pending JP2024088740A (ja) | 2018-10-31 | 2024-04-08 | 睡眠時無呼吸を治療するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062027A Pending JP2024088740A (ja) | 2018-10-31 | 2024-04-08 | 睡眠時無呼吸を治療するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20210401790A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873454A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022506113A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210084481A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112930179A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019370091A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117766A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021004883A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020091862A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523876A (ja) * | 2021-06-17 | 2024-07-02 | アプニメッド,インコーポレイテッド(デラウェア) | 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 |
| MX2024007768A (es) * | 2021-12-22 | 2024-07-01 | Bayer Ag | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. |
| IL313648A (en) * | 2021-12-22 | 2024-08-01 | Bayer Ag | Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| CN119789855A (zh) * | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| AT414238B (de) * | 2001-03-06 | 2006-10-15 | Lilly Co Eli | Neues hydroxyliertes 3-phenoxy-3-phenyl-1- aminopropan und dieses aminopropan enthaltende pharmazeutische formulierung |
| PT1691811E (pt) * | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
| US20080145318A1 (en) * | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
| JP2012176958A (ja) * | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | (r)−オキシブチニンおよび(r)−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| EP4011370A1 (en) * | 2014-07-22 | 2022-06-15 | Magnolia Cns, Llc | Pharmaceutical compositions and method for the treatment of symptoms of panic and anxiety using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations |
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
-
2019
- 2019-07-23 CA CA3117766A patent/CA3117766A1/en active Pending
- 2019-07-23 EP EP19749533.6A patent/EP3873454A1/en active Pending
- 2019-07-23 AU AU2019370091A patent/AU2019370091A1/en not_active Abandoned
- 2019-07-23 WO PCT/US2019/043065 patent/WO2020091862A1/en not_active Ceased
- 2019-07-23 US US17/289,832 patent/US20210401790A1/en not_active Abandoned
- 2019-07-23 MX MX2021004883A patent/MX2021004883A/es unknown
- 2019-07-23 JP JP2021523282A patent/JP2022506113A/ja active Pending
- 2019-07-23 CN CN201980071524.0A patent/CN112930179A/zh active Pending
- 2019-07-23 KR KR1020217013074A patent/KR20210084481A/ko not_active Ceased
-
2021
- 2021-04-28 MX MX2024013184A patent/MX2024013184A/es unknown
-
2024
- 2024-04-08 JP JP2024062027A patent/JP2024088740A/ja active Pending
- 2024-12-18 US US18/985,496 patent/US20250114321A1/en not_active Abandoned
-
2025
- 2025-06-30 US US19/254,231 patent/US20250325510A1/en not_active Abandoned
-
2026
- 2026-02-12 US US19/537,913 patent/US20260165996A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101730530B (zh) | 他喷他多的滴定 | |
| US20260014163A1 (en) | Use of reboxetine to treat fibromyalgia | |
| US8512751B2 (en) | Pharmaceutical compositions for sleep disorders | |
| JP6479670B2 (ja) | 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法 | |
| JP2020517719A5 (cg-RX-API-DMAC7.html) | ||
| JP2019116494A (ja) | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 | |
| JPH08208471A (ja) | 薬物反応の増強作用 | |
| JP2008524332A5 (ja) | 睡眠障害のための医薬組成物 | |
| JP2022519721A5 (cg-RX-API-DMAC7.html) | ||
| JP2025084754A5 (cg-RX-API-DMAC7.html) | ||
| US12115165B2 (en) | Use of reboxetine to treat narcolepsy | |
| RS51452B (sr) | Orodisperzivne farmaceutske smeše za oralnu, oromukozalnu ili sublingvalnu primenu agomelatina | |
| US20210100808A1 (en) | Use of reboxetine to treat narcolepsy | |
| JP2020533415A (ja) | ナルコレプシーの処置におけるガボキサドールの使用 | |
| JP2006506461A (ja) | ミルナシプランのパルス型放出組成物 | |
| US12616702B2 (en) | Use of reboxetine to treat narcolepsy | |
| US20070219201A1 (en) | Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders | |
| TWI790510B (zh) | 瑞波西汀治療神經系統障礙的用途 | |
| JP2024511091A5 (cg-RX-API-DMAC7.html) | ||
| US20260014165A1 (en) | Use of esreboxetine to treat nervous system disorders such as fibromyalgia | |
| JP2025500344A5 (cg-RX-API-DMAC7.html) | ||
| CN116194092A (zh) | 经口给予制剂 | |
| JP2025527796A (ja) | 睡眠時無呼吸を治療するための方法及び組成物 |